SteelPeak Wealth’s Pacific Biosciences PACB Stock Holding History

SteelPeak Wealth’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-47,872	Closed	-$63.2K	–	687
2026 Q1	$63.2K	Sell	47,872 -33,550	-41%	-$60K	﹤0.01%	560
2025 Q4	$152K	Buy	81,422 +51,492	+172%	+$98.9K	0.01%	509
2025 Q3	$38.3K	Buy	29,930 +14,626	+96%	+$19.8K	﹤0.01%	575
2025 Q2	$19K	Buy	+15,304	New	+$17.7K	﹤0.01%	560
2025 Q1	–	Sell	-10,236	Closed	-$18.7K	–	652
2024 Q4	$18.7K	Buy	+10,236	New	+$20K	﹤0.01%	560
2024 Q2	–	Sell	-94,589	Closed	-$355K	–	590
2024 Q1	$355K	Buy	+94,589	New	+$554K	0.02%	342
2023 Q3	–	Sell	-15,848	Closed	-$211K	–	495
2023 Q2	$211K	Buy	+15,848	New	+$193K	0.01%	387
2021 Q4	–	Sell	-14,003	Closed	-$358K	–	455
2021 Q3	$358K	Buy	14,003 +6,951	+99%	+$206K	0.02%	298
2021 Q2	$247K	Buy	+7,052	New	+$205K	0.02%	364

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SteelPeak Wealth's PACB Position: Q2 2026 in Review

SteelPeak Wealth sold out of Pacific Biosciences (PACB) in Q2 2026, closing a stake of 47,872 shares — an estimated $63.2K sold.

SteelPeak Wealth first reported a position in PACB in Q2 2021 and held it in 9 quarters. The position peaked at $358K in Q3 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

SteelPeak Wealth reported no remaining Pacific Biosciences position as of Q2 2026 after selling out during the quarter.
SteelPeak Wealth sold 47,872 Pacific Biosciences shares in Q2 2026, an estimated $63.2K.
SteelPeak Wealth first reported a position in Pacific Biosciences in Q2 2021 and held it in 9 quarters.
SteelPeak Wealth's Pacific Biosciences position peaked at $358K in Q3 2021.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on SteelPeak Wealth's 13F filing for Q2 2026, filed 13 Jul 2026.